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Cardiac cell therapy with mesenchymal stem cells (MSCs) represents a promising treatment approach for end-
stage heart failure. However, little is known about the underlying mechanisms and the fate of the transplanted 
cells. The objective of the presented work is to determine the feasibility of magnetic resonance imaging (MRI) 
and in vivo monitoring after transplantation into infarcted mouse hearts using a clinical 3.0 T MRI device. 
The labeling procedure of bone marrow-derived MSCs with micron-sized paramagnetic iron oxide particles 
(MPIOs) did not affect the viability of the cells and their cell type-defining properties when compared to 
unlabeled cells. Using a clinical 3.0 T MRI scanner equipped with a dedicated small animal solenoid coil, 
105 labeled MSCs could be detected and localized in the mouse hearts for up to 4 weeks after intramyocardial 
transplantation. Weekly ECG-gated scans using T1-weighted sequences were performed, and left ventricular 
function was assessed. Histological analysis of hearts confirmed the survival of labeled MSCs in the target area 
up to 4 weeks after transplantation. In conclusion, in vivo tracking of labeled MSCs using a clinical 3.0 T MRI 
scanner is feasible. In combination with assessment of heart function, this technology allows the monitoring of 
the therapeutic efficacy of regenerative therapies in a small animal model. 
Key words: Magnetic resonance imaging (MRI); Mesenchymal stem cells (MSCs); Cell tracking; Cardiac 
function; Myocardial infarction
INTRODUCTION
Heart failure is the major cause of death in industrial 
countries and represents a significant health problem 
throughout the world (21,34). Myocardial infarction and 
ischemic heart disease lead to irreversible loss of myocar-
dium, formation of scar tissue, and, in turn, deterioration 
of cardiac pump function. Since the heart has poor regen-
eration capabilities, it fails to reconstitute necrotic tissue 
(27,30). Thus, heart transplantation or mechanical assist 
devices represent the only therapeutic option for end-stage 
heart failure (4). 
Cardiac cell therapy is an emerging and promising 
approach for the regeneration of the heart (35). In contrast 
to pharmacological and surgical approaches, cell-based 
therapies potentially may improve the myocardial regen-
eration (i.e., after myocardial infarction). In clinical trials, 
predominantly bone marrow-derived cells have been applied, 
showing encouraging results (23). Within the bone marrow-
derived cell populations, mesenchymal stem cells (MSCs) 
have emerged as a promising subpopulation (17) with spe-
cific therapeutically effective properties (6). MSCs migrate 
to the site of tissue injury (16,38) and induce paracrine 
effects [i.e., immunomodulation (36,40) and angiogenesis 
induction (14,15)]. However, there is only limited informa-
tion regarding the underlying mechanisms and the fate of the 
transplanted cells. Therefore, there is an essential need for 
noninvasive methods to localize transplanted cells in vivo. 
In the present study, we sought to determine the fate of 
transplanted bone marrow-derived MSCs and assess the 
changes in cardiac function in a cryoinjury-induced murine 
model of cardiac infarction applying a clinical 3.0 T mag-
netic resonance imaging (MRI) scanner.
1972 DREY ET AL.
MATERIALS AND METHODS
Animal Care
All animals received humane care in compliance with 
the National Institutes of Health and National Society of 
Medical Research guidelines.
Isolation and Expansion of Murine Mesenchymal  
Stem Cells
MSCs were isolated based on protocols described 
previously (28,37). Briefly, nucleated bone marrow cells 
(BMCs) were obtained from 8-week-old C57BL/6 mice 
(bred in house) by flushing the long bones with phosphate-
buffered saline (PBS, Invitrogen, Carlsbad, CA, USA). 
Total BMC yield was quantified after red blood cell lysis 
with a commercially available solution (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) using a hemacytometer 
(Roth, Karlsruhe, Germany) and then cultured at a density 
of 1.5 ´  106 BMCs/cm2, with a custom-made MSC culture 
media (PAN Biotech, Aidenach, Germany) supplemented 
with 2.5 ng/ml human basic fibroblast growth factor 
(bFGF, R&D Systems, Wiesbaden, Germany), 100 U/ml 
penicillin, and 100 μg/ml streptomycin (both Invitrogen). 
The cultures were incubated at 37°C and 5% CO2 in a 
humidified incubator. MSCs were further cultured for 6–8 
weeks and continuously passaged at a confluence of 80% 
using trypsin (0.5 g/L) and ethylenediaminetetraacetic 
acid (EDTA, 0.2 g/L, both Invitrogen) until a proliferative, 
homogenous MSC population was achieved. 
In Vitro Differentiation Assays
In order to confirm the presence of MSCs, the cells 
were further differentiated in vitro into adipo-, chondro-, 
and osteogeneic cell lines.
For adipogenesis, MSCs were cultured in adipogen-
esis differentiation medium composed of low-glucose 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), 
fetal bovine serum (10%, Lonza, Basel, Switzerland), dex-
amethasone (1 μM, Sigma-Aldrich, Steinheim, Germany), 
3-isobutyl-1-methylxanthine (IBMX, 0.5 mM, Sigma-
Aldrich), insulin (10 μg/ml, Roche, Grenzach-Whylen, 
Germany), and indomethacin (100 μm, Sigma-Aldrich). 
After 21 days, the cells were stained with Oil Red 
(Sigma-Aldrich) to visualize the lipid vesicles.
To induce chondrogeneic differentiation, MSCs were 
centrifuged for 15 min at 150 ´  g, and chondrogeneic 
differentiation medium (StemPro, Invitrogen) was used 
according to the manufacturer’s protocol. The small clus-
ter that was formed from the pelleted cells was cryosec-
tioned and stained with Alcian blue (Roth) to visualize 
chondrogeneic extracellular deposits of hyaluronic acids.
Osteogeneic differentiation was induced by culturing 
MSCs for 15 days in osteogenesis differentiation medium, 
composed of low-glucose DMEM, fetal bovine serum 
(10%, Lonza), dexamethasone (0.1 μM, Sigma-Aldrich), 
ascorbic acid 2-phosphate (0.2 mM, Sigma-Aldrich), 
glycerol 2-phosphate (10 mM, Roth), and l-glutamine 
(2 mM). Differentiation medium was changed twice per 
week. After 15 days, cells were stained with silver nitrate 
(Roth) following the von Kossa protocol. The calcium 
deposits were visualized by treatment with 1% pyrogallol 
(Roth) and 5% sodium thiosulfate (Roth).
Fluorescence-Activated Cell Sorting (FACS):  
Surface Antigen Expression
The expression of MSC surface marker antigens was 
analyzed by FACS. Cells at 106 per sample were stained 
with fluorescently labeled anti-cluster of differentiation 
45 (CD45; fluorescein isothiocyanate, FITC), anti-stem 
cell antigen 1 (Sca-1; phycoerythrin, PE), anti-CD44 
(phycoerythrin/cyanine 7, PE/Cy7), and anti-CD11b (PE/
Cy7)-specific antibodies (all BD, Heidelberg, Germany) 
at a concentration of 0.125 μg/ml for 10 min at 4°C. 
Matching isotypes were used as controls (BD). A mini-
mum of 5 ´  105 cells was analyzed using a FACS-Calibur 
cytometer and Cellquest Pro v6 software (BD). 
Cell Labeling
MSCs were labeled with Micron-sized iron oxide par-
ticle (MPIO) microspheres (product No. MC03F/9781, 
Bangs Laboratories, Fishers, IN, USA), serving as MRI 
contrast agent and histologicalmarker. These MPIOs were 
0.9 μm in diameter and composed of polystyrene with 
62% (w/w) iron oxide and labeled with a red fluorescent 
dye (Flash Red). For the establishment of optimal label-
ing conditions for MSCs decreasing amounts of MPIOs 
from 1.8 ´  108 to 0.7 ´  106 MPIOs per cm2 of cell culture 
surface area were used, corresponding to 100 μl to 0.4 μl 
MPIO suspension per mlmedium. In order to detect trans-
planted, surviving MSCs containing MPIOs, MSCs were 
colabeled with the fluorescent vital cell stain Vybrant 
1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethylindocarbocyanine 
perchlorate (DiI; Invitrogen).
Proliferation Assay
Proliferation of MSCs was assessed using the 2,3-
bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)
carbonyl)-2H-tetrazoliumhydroxide (XTT) assay (Appli-
chem, Darmstadt, Germany) following the manufacturer’s 
instructions. Briefly, cells were seeded at 500 cells per cav-
ity on a 96-well plate (BD). At defined time points, the 
medium was replaced by 100 μl medium plus 50 μl XTT 
working solution and incubated for 3 h. The absorbance 
of orange XTT reduced formazan compounds was mea-
sured in a spectrophotometer (Tecan Sunrise, Crailsheim, 
Germany) at 450 nm with a reference measurement at 
620 nm. The correlation of absorbance and number of 
viable cells was determined by a standard curve from 
serial dilutions of defined cell numbers. 
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Animal Disease Model/Intramyocardial Transplantation
The myocardial injury was induced by cryoinfarction 
in male, 8- to 10-week-old C57BL/6 mice. After induction 
of general anesthesia with 5% isoflurane (Abbott, Abbott 
Park, IL, USA) and O2/N2O (1:1), the animals were intu-
bated, and anesthesia was maintained with 1.5% isoflu-
rane. A liquid nitrogen cooled probe was placed on the left 
ventricle thrice for 5 s through a left-sided thoracotomy. 
Immediately after cryoinfarct induction, 105 labeled MSCs 
in 10 μl PBS were transplanted by a single intramyo-
cardial injection into the peri-infarct area (n = 5) using a 
25-μl syringe (Hamilton, Bonaduz, Switzerland) with 
a 27-gauge cannula (BD). Sham animals (n = 5) received 
10 μl PBS only. After cell injection, the chest was closed 
and the thoracic cavity was evacuated. Animals without 
any surgical treatment (n = 5) were used as healthy controls.
MR Image Acquisition
Transplanted MSCs were identified, and the cardiac 
function was assessed in vivo using a clinical 3.0 T MRI 
scanner (80 mT/m max strength, slew rate: 200 mT ´  ms/m, 
Intera Achieva, Phillips Medical Systems, Best, Netherlands) 
as described previously (2,11,22). To enhance signal-to- 
noise-ratio, the MRI device was equipped with a dedicated 
experimental small animal solenoid coil (Phillips Medical 
Systems, Best, Netherlands). For electrocardiography (ECG) 
gating, MRI-compatible pediatric ECG electrodes (blue sen- 
sor BR/BRS, Ambu A/S, Baltorpbakken, Denmark) were 
attached to the animals’ paws. Serial MRI scans of trans-
planted hearts were performed weekly for 4 weeks after 
infarct induction. Mice were anesthetized with 1.25% iso-
flurane (1 L/min O2). Long-axis images of the left ventricle 
were obtained by ECG-gated sagittal scans of six slices 
with six cardiac phases to localize the MPIO-labeled MSCs. 
Cardiac function was assessed by ECG-gated acquisition 
of transversal images of six slices with 12 cardiac phases 
of the left ventricle between the end-systolic and end- 
diastolic state. Setup of MRI was as follows: T1-weighted 
fast gradient echo single-shot sequence, repetition time 
(TR) = 15 ms, echo time (TE) = 4 ms, flip angle = 15°, field 
of view (FOV) = 80 ´  80 mm, acquisition (ACQ) voxel reso-
lution = 0.30 ´  0.30 ´  1.00 mm, reconstruction (REC) voxel 
resolution = 0.16 ´  0.16 ´  1.00 mm, matrix = 268 ´  267, six 
contiguous slices at 1-mm slice thickness. Acquisition time 
for localization and cardiac function per animal was about 
40–45 min. Normothermia of the mice was maintained by 
a heating system integrated in the solenoid coil.
MRI Image Analysis
For documentation of MSC localization, long-axis 
images of the left ventricle were analyzed for signal voids 
within the ventricular wall (which were not present in 
sham operated animals) and saved as image files using 
visualization software DICOM viewer R2.5 v1.1 (Philips). 
Transversal MRI images covering the complete left ventri-
cle were used for semiautomatical assessment of endocar-
dial and epicardial contours. Left ventricular end-systolic 
(LVES) and end-diastolic (LVED) volumes were calculated 
using image analysis software Segment v1.8 (Medviso, 
Lund, Sweden). Left ventricular ejection fraction (LVEF) 
was calculated from LVES and LVED volumes. Data were 
analyzed independently by three experienced researchers. 
Sagittal images showing signal voids in the left ven-
tricular walls were analyzed for assessment of signal void 
areas and signal void intensities by ImageJ software v1.42q 
(http://rsbweb.nih.gov/ij/). Background signal void intensi-
ties were determined from septum areas. The threshold for 
specific signal void intensity was defined as less than 50% 
signal intensity of background. Each slice was scanned 
for areas with signal intensities below the threshold level. 
Signal voids in the left ventricular wall were then quanti-
fied for area size and mean signal intensity.
Histochemistry
Mice were euthanized after the final MRI assessment, 
hearts were excised, flushed with PBS, and immediately 
cryopreserved using Tissue-Tek O.C.T. (Sakura Finetek, 
Staufen, Germany). Hearts were cryosectioned (10 μm) 
and analyzed by histochemistry. Masson’s trichrome 
staining (MTC, Roth, Karlsruhe, Germany) was performed 
to confirm the myocardial infarction area. The presence 
of MPIO-labeled MSCs was confirmed by fluorescence 
detection ( Flash Red ) and iron oxide-specific Prussian 
blue staining (Roth). Microphotographic documentation 
was performed using an inverted Nikon Eclipse Ti-U 
microscope (Nikon, Düsseldorf, Germany).
Statistical Analysis
All data were expressed as mean ± 1 standard devia-
tion. Comparison of groups was performed using one-
way analysis of variance (ANOVA) followed by post hoc 
Bonferroni test. A value of p ≤ 0.05 was considered statis-
tically significant. The statistical analysis was performed 
using IBM SPSS Statistics software package, release 19 
(IBM Corp., Somers, NY, USA).
RESULTS
Murine Bone Marrow MSC Isolation
Mesenchymal stem cells could be successfully isolated 
from bone marrow of C57BL/6 mice. In order to reproduc-
ibly achieve proliferative MSC cultures, a minimum of 
106/cm2 BMCs were seeded in specifically optimized 
medium. The first culture media change was performed after 
48 h, followed by media changes every 3 days, resulting in 
a confluent monocell layer of plastic adherent cells. After 
6–8 weeks and at passages 3–4, a morphologically homo-
geneous, proliferative population of spindle-shaped cells 
was the predominant cell type and was used for subsequent 
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characterization and transplantation experiments. Following 
this protocol, a typical MSC isolation, starting with bone 
marrow from three 6-week-old mice, yielded a total MSC 
number of at least 30 ´  106 cells at passage 5.
Labeling of MSCs With Paramagnetic MPIOs
In order to track transplanted intramyocardial cells in 
vivo in a murine model using a clinical MRI scanner, the 
MSCs were labeled with paramagnetic fluorescent MPIOs. 
The ratio of labeled cells and the labeling intensity for 
MSCs incubated with decreasing amounts of MPIOs were 
assessed by flow cytometry in order to establish opti-
mal labeling conditions. MPIOs at 0.7 ´  106/cm2 resulted 
in about 80% MSC labeling efficiency, which could be 
further increased up 99% (11.2 ´  106/cm2) (Fig. 1). 
The cell-labeling intensity was determined by the mean 
fluorescence intensity of the labeled fraction of the MSCs. 
Here, a 20-fold increase in intensity could be observed bet-
ween the lowest and highest MPIO concentration (Fig. 1). 
Thus, populations of MSCs can be efficiently and com-
pletely labeled with moderate amounts of MPIOs with the 
option of gradually enhancing the intensity of the labeling 
by increasing the amount of MPIOs applied.
Characterization and In Vitro Differentiation of  
Labeled MSC
In order to assess the effects of MPIO labeling of MSCs, 
cells from passage 6 were labeled with 11.2 ´  106 MPIOs/
cm2. The morphology of the MSCs was not affected by the 
MPIO labeling conditions and the cells remained in spindle 
shape (Fig. 1A–D). The viability of unlabeled and labeled 
MSCs was compared by assessing their proliferation rates, 
which showed no significant difference (Fig. 1G). Both 
cell populations doubled approximately every 36 h.
Additionally, the MSCs were analyzed for the consen-
sual MSC surface marker expression profile by FACS. 
There was no significant difference between both groups, 
which were negative for CD11b and CD45 and positive for 
Figure 1. Labeling of murine MSCs with paramagnetic micron-sized iron oxide particles (MPIOs). (A–D) Morphology of mesen-
chymal stem cells (MSCs) and cytoplasmic distribution of MPIOs. Microphotographs of unlabeled MSCs (A) and MSCs labeled with 
5.6 ´  106 (B), 11.2 ´  106 (C), and 22.5 ´  106 (D) MPIOs/cm2. Flash Red fluorescent MPIOs are shown as rough, uneven staining. Nuclei 
stained with DAPI are shown as smooth, even staining. Scale bar: 50 μm. (E) Labeling efficiency. Ratios of MPIO-labeled MSCs deter-
mined by fluorescence-activated cell sorting (FACS) analysis of Flash Red-positive cells. (F) Labeling intensity. Mean fluorescence 
intensities of labeled MSCs determined by FACS analysis of Flash Red-positive cells. (G) Proliferation. Cells numbers were measured 
daily for 1 week for unlabeled and labeled MSCs using the XTT proliferation assay. 
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MSC-specific markers CD44 (63.4 ± 15.2% vs. 64.1 ± 4.1%, 
p = 0.92) and Sca-1 (98.0 ± 0.9% vs. 97.8 ± 0.8%, p = 0.77). 
The MPIO labeling had no negative effect on the in 
vitro differentiation potential of MSCs (Fig. 2A–C). 
Labeled MSCs also showed a proper differentiation along 
adipogeneic, chondrogeneic and osteogeneic lineages 
when labeled with 11.2 ´  106 MPIOs/cm² (Fig. 2D–F).
Histochemistry
The myocardial infarct region was detected by MTC 
staining and confirmed a significant transmural myocar-
dial cryoinjury (Fig. 3A, B). Sections of hearts explanted 
4 weeks after transplantation were screened for MPIO-
labeled MSCs after Prussian blue staining and confirmed 
by colocalized detection of Flash Red fluorescence 
(Fig. 3C, D). Transplanted MSCs could be detected in 
the myocardium in three of five animals. In two hearts, 
we found MPIOs in the peri-infarct region continuously 
over 80 and 50 sections (10 μm thickness), respectively. 
In both hearts, MPIOs could also be detected within the 
fibrotic tissue of the infarct scar. Furthermore, in both 
cases, a connecting trail of signal between the large sig-
nal areas in the peri-infarct region and the smaller area 
within the fibrotic infarct region could be detected (Fig. 
3B–D). In one animal, the cells were localized also in 
the septum far from the infarct region. The detection of 
viable MPIO-labeled MSCs was confirmed by colocal-
ization of two markers, Flash Red fluorescent MPIOs and 
vital stain Vybrant DiI, up to 4 weeks after transplantation 
(Fig. 3E–G).
In Vivo Tracking of Transplanted, Labeled MSC
The T1-weighted image acquisition resulted in a high spa-
tial resolution while the detectability of hypointense signal 
voids was not compromised (data not shown). Signal voids 
from MPIOs, shown as darker areas compared to the back-
ground tissue signal, could be detected in four of five MSC-
transplanted animals over the course of 4 weeks (Fig. 4A, B), 
whereas no signal voids were observed in sham-transplanted 
animals. MRI images of sham-transplanted mice did not 
show signal voids in the ventricular wall. In transplanted ani-
mals, the signal voids were detectable on two to three sagittal 
slices and three to four transversal slices (1 mm slice thick-
ness without gaps) and were located in the cryoinfarction 
region in the anterior left ventricular wall. The location of 
the signal void remained constant over the observational 
period of 4 weeks. An approach to quantify the detectable 
signal void was performed in order to compare changes over 
time and among experiments. Quantitative analysis of scans 
from animals with signal voids accessible for analysis (n = 3) 
showed a tendency for reduction of signal void area and 
increase of signal void intensity over 4 weeks, but without 
significant differences between time points (Fig. 4C).
Cardiac Function
When compared to healthy control mice, which had 
not received any surgical intervention, the LVEF of cryo-
infarcted mice with sham injection was significantly 
reduced throughout the entire observational period of 
4 weeks (healthy: 65.2 ± 4.7%; sham animals: 1 week after 
transplantation: 48.9 ± 4.5%, week 2: 44.8 ± 3.4%, week 3: 
Figure 2. In vitro differentiation potential of murine MSCs labeled with paramagnetic MPIOs Unlabeled MSCs (A–C) and MSCs 
labeled with 11.2 ´  106 microspheres/cm2 (D–F) were submitted to specific cell culture conditions inducing adipogenic (A, D), chondro-
genic (B, E), and osteogenic (C, F) differentiation. (A, D) Lipid vacuoles of adipocytes were stained with Oil Red. (B, E) Chondrogenic 
deposits of hyaluronic acids were stained with Alcian blue. (C, F) Osteogenic deposits of calcium were stained black by van Kossa 
staining. Scale bars: 100 μm (A, D) and 50 μm (B, C, E, F).
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47.0 ± 4.9%, week 4: 49.4 ± 6.0%) (Fig. 5). Cryoinfarcted 
mice with MSC transplantation showed a trend to bet-
ter LVEF compared to the sham-treated animals without 
reaching statistical significance. LVEF was significantly 
lower in the MSC-transplanted group compared to 
healthy controls over the first 3 weeks, but not at week 4 
(MSC-transplanted animals: 1 week after transplantation: 
49.4 ± 3.7%, week 2: 49.5 ± 3.3%, week 3: 52.7 ± 3.9%, 
week 4: 54.3 ± 6.5%) (Fig. 5).
DISCUSSION
In the present study we demonstrated the following: 
(a)  MSCs could be labeled efficiently with paramagnetic 
MPIOs without impairing MSC specific features (i.e., 
proliferation capacity, surface antigen expression and 
in vitro differentiation potential). 
(b)  Labeled cells were localized after intramyocardial 
transplantation to a murine model and parameters rel-
evant for heart function were assessed using a clinical 
3.0 T MRI device.
(c)  The MRI-based localization of MPIO-labeled MSCs 
in the myocardium could be confirmed and analyzed 
histologically.
MSC Isolation 
The isolation and expansion of homogeneous popu-
lations of murine MSCs is known to be challenging. 
Mouse strain-related variances, differences in methods of 
Figure 3. Histological analysis of MSC-transplanted hearts. (A, B) Representative sections of a heart explanted 4 weeks after cryo-
infarction and intramyocardial transplantation of 105 labeled MSCs. Masson’s trichrome (MTC) staining showing myocardial cells 
(dark staining) and fibrotic tissue (light staining) from scarring at the site of infarction on the left ventricular wall. (A) The maximum 
infarction area of a representative heart. (B) Site of cell injection (100 μm apart from A; scale bars: 500 μm). (C, D) Detailed views 
from inset in (A) (rotated 90° counterclockwise): MPIOs were detected by Prussian blue staining (dark staining, C) and colocalization 
by Flash Red fluorescence signal (light staining, D). Scale bars: 100 μm. (E–G) Representative section of a heart explanted 4 weeks 
after cryoinfarction and intramyocardial transplantation of 105 MSCs labeled with MPIOs and Vybrant DiI: (E) fluorescent signal 
from DiI, (F) fluorescent signal from Flash Red, (G) merged images E and F (nuclei: staining not evident). Vital-labeled MSCs were 
confirmed by colocalization of Vybrant DiI and MPIOs. Scale bar: 50 μm.
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isolation, and cell culture conditions make results hard to 
reproduce and to compare (29,32). The original method to 
isolate murine MSCs from bone marrow is based on their 
ability to adhere to plastic surfaces (10). In contrast to 
published methods (37), we established an MSC isolation 
protocol, plating bone marrow aspirate cell suspensions at 
high MSC densities, without further selection procedures 
like density gradient centrifugation (12) and immune-
magnetic enrichment or depletion (1,31). This resulted 
in a reproducibly improved yield of MSCs, independent 
of the strain and gender of the donor animals used.
MSC Labeling
In order to track and study the fate of transplanted 
cells in vivo by MRI, the target cells were labeled with 
paramagnetic MPIOs. MSCs showed a highly efficient 
uptake of MPIOs by phagocytosis, omitting the need of 
transfection procedures (9,24,41). There were no detri-
mental effects on viability or cell type-specific properties, 
including viability, proliferation rate, surface markers 
expression, and in vitro differentiation potential.
Figure 5. Time course of cardiac function after cryoinfarction 
and cell transplantation. The left ventricular ejection fraction 
(LVEF) was determined by analysis of short-axis MR images. 
While the LVEF of MSC-transplanted animals showed a trend 
for an increased LVEF, the improvement did not reach statistical 
significance. LVEF of transplanted mice differed significantly 
(*p < 0.05) compared to healthy control animals (65.2 ± 4.7%) 
for all time points, except for the MSC group 4 weeks after 
transplantation. Data are shown as mean ± 1 standard deviation; 
all groups are n = 5.
Figure 4. In vivo cell tracking by MRI. (A, B) Representative images from sagittal (A) and transversal (B) cine data sets from MSC-
transplanted mice after myocardial cryoinfarction. Signal voids are clearly visible in the left ventricular wall. Magnetic resonance 
imaging (MRI) measurements were performed on a weekly basis for 4 weeks (1w–4w) after transplantation using a 3.0 T MRI scanner. 
(C) Quantitative analysis of signal voids. Images from MRI measurements over 4 weeks after transplantation of labeled cells were 
quantitatively analyzed for signal voids of the left ventricular wall and normalized to values of the first measurement on week 1. Size 
and average signal intensity of signal voids were assessed by densitometry. Data are shown as mean ± 1 standard deviation from three 
independent measurements. CNR, contrast-to-noise ratio.
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An alternative method for in vivo cell tracking is 
the detection of luciferase activity by bioluminescence 
imaging (BLI). Since this approach is based on genetic 
modification of the cells, the clinical perspective remains 
questionable. But at least for experimental approaches, 
the analysis of cell survival is more feasible by BLI than 
by MRI (5), despite disadvantages including lower sen-
sitivity and tissue penetration. MRI provides anatomical 
details in high resolution, allowing three-dimensional 
localization of transplanted cells in the anatomical con-
text of the host tissue. Additionally, cine sequences can be 
acquired for the analysis of cardiac function. For the pur-
pose of this study, MRI proved its superiority with regard 
to BLI, since it focused on the localization of transplanted 
cells and the determination of changes of cardiac function 
over time.
Cell Tracking
Most of the published works focusing on in vivo cell 
tracking either applied clinical 3.0 T MRI devices in large 
animal models (13,19) or experimental high Tesla MRI 
devices optimized for small animals (i.e., mice and rats) 
(3,7,8). The aim of this study was to establish a broadly 
accessible setup for in vivo cell tracking and the evalua-
tion of cardiac function for small animal models using a 
clinical 3.0 T MRI device.
The MRI scanner used in this study was able to detect a 
minimum of 104 labeled MSCs injected into the hind limb 
of mice using T1-weighted sequences (data not shown). 
T1-weighted sequences were chosen, despite the fact 
that T2*-weighted sequences have a superior sensitivity 
for iron oxide (42), since they display higher anatomi-
cal detail, necessary for the accurate analysis of cardiac 
function, while maintaining sufficient sensitivity for cell 
tracking. We transplanted 105 labeled MSCs into infarcted 
mouse myocardium and were able to detect signal voids 
in the left ventricular wall over a time span of 4 weeks in 
vivo. Whole-body scans for the detection of transplanted 
MSC in other regions and organs have not been per-
formed. Organ-specific optimized MRI sequences would 
be necessary in order to differentiate microsphere gen-
erated signal voids from tissue background. The neces-
sary scan time to assess all potential target organs would 
have exceeded the duration of general anesthesia in mice. 
Nevertheless, Muller-Ehmsen and coworkers already 
demonstrated the early translocation of intramyocardially 
transplanted MSCs to other organs, that is, spleen, lungs, 
and kidneys by polymerase chain reaction (26).
Using sagittal slices from MRI, the LVEF was assessed 
on a weekly basis for 4 weeks after transplantation. When 
comparing the development of LVEF of MSC-transplanted 
versus sham-transplanted mice, there was no significant 
difference between the groups at 4 weeks.
In most cardiac cell therapy studies, high numbers of 
cells were transplanted in order to maximize the regenera-
tive efficacy (20,25,33). Since the aim of this study was to 
establish the use of a clinical 3.0 T MRI scanner for cell 
tracking in mice and to determine the detection threshold 
for transplanted cells, the number of transplanted cells was 
significantly lower than the proposed therapeutically effi-
cient cell dosage resulting only in minor functional effects, 
as expected.
The quantitative assessment of the signal voids showed 
decreasing size of the void area, while the intensity increased, 
suggesting that the transplanted cells condense in the host 
tissue. Histological analysis confirmed the localization of 
MPIOs within the targeted peri-infarct region of the left ven-
tricular wall. Furthermore, we found trails of MPIOs from 
the injection site to the infarction area, indicating a migra-
tion of labeled MSCs towards the site of injury, as described 
previously (18). 
In two of five animals receiving labeled MSCs, we 
were not able to detect cells by histochemistry. In one of 
these two animals, specific signal voids in the ventricular 
wall were also not detectable by MRI. Intramyocardial 
injections into murine hearts are known to be techni-
cally challenging. The retention and survival of the trans-
planted cells is low due to mechanical loss, wash-out, 
and apoptosis (43). Multiple injections, the monitoring 
of transplanted cells immediately after injection by bio-
luminiscene and the addition of gelling substances to 
the cell suspensions are options to improve the quality 
of intramyocardial cell transplantation.
One major limitation of in vivo MR imaging using 
MPIOs as a contrast agent is the inability to distinguish 
whether the contrast agent remains internalized within 
the labeled cell or is released and either deposited in 
the tissue or reinternalized by other cells (i.e., mac-
rophages) (39). Histological analysis of sections from 
hearts explanted 4 weeks after transplantation of 105 
MSCs labeled with MPIOs and the vital stain Vybrant 
DiI showed a colocalization of both stains confirming the 
retention of MPIOs within vital MSCs. Nevertheless, the 
histochemistry-based assessment does not allow quanti-
tative analysis. A periodical analysis, that is, on a weekly 
basis, may provide interesting information about the cell 
retention kinetics of MPIO-labeled MSCs without quan-
titative evidence.
In summary, the presented work provides a simple and 
highly efficient protocol for labeling, transplantation, and 
MR imaging of murine MSCs, allowing simultaneous 
cell tracking and evaluation of cardiac function in a small 
animal model using a clinical MRI device. 
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